Picture of Prothena logo

PRTA — Prothena News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapHigh Flyer

Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview

Prothena Corporation PLC <PRTA.OQ> expected to post a loss of 39 cents a share - Earnings Preview 
  • Prothena Corporation PLC PRTA.OQ PRTA.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2026

  • The Dublin Ireland-based company is expected to report a 540.2% increase in revenue to $28.295 million from $4.42 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Prothena Corporation PLC is for a loss of 39 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Prothena Corporation PLC is $20.00, about 140.1% above its last closing price of $8.33

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2026

-0.36

-0.35

0.61

Beat

275.1

Dec. 31 2026

-0.59

-0.56

-0.40

Beat

28.4

Sep. 30 2025

-0.81

-0.69

-0.68

Beat

1​

Jun. 30 2025

-1.72

-1.32

-1.73

Missed

-31.4

​​Mar. 31 2025

-0.95

-0.97

-1.12

Missed

-15.1

Dec. 31 2024

-1.06

-1.04

-1.08

Missed

-3.6​

Sep. 30 2024

-1.17

-1.18

-1.10

Beat

6.6

Jun. 30 2024

-1.02

-1.05

1.22

Beat

215.8

This summary was machine generated August 4 at 22:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Prothena

See all news